<DOC>
<DOCNO>EP-0637334</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PEPTIDES HAVING A GDP EXCHANGE FACTOR ACTIVITY, NUCLEIC ACID SEQUENCES CODING FOR SAID PEPTIDES, PREPARATION AND UTILIZATION
</INVENTION-TITLE>
<CLASSIFICATIONS>C12N1509	C07K1624	A61K3944	A61P3500	C07H2100	A61K3800	G01N33577	C12P2102	A61K3944	C07K1452	C12R119	A61K3800	C12Q168	C12N1512	A61K39395	C07K1618	C12P2102	C12P2108	C12Q168	C12N1512	C12P2108	C07K14435	C07K1447	A61K39395	C07H2104	G01N33577	A61P3500	C12N1509	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12N	C07K	A61K	A61P	C07H	A61K	G01N	C12P	A61K	C07K	C12R	A61K	C12Q	C12N	A61K	C07K	C12P	C12P	C12Q	C12N	C12P	C07K	C07K	A61K	C07H	G01N	A61P	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12N15	C07K16	A61K39	A61P35	C07H21	A61K38	G01N33	C12P21	A61K39	C07K14	C12R1	A61K38	C12Q1	C12N15	A61K39	C07K16	C12P21	C12P21	C12Q1	C12N15	C12P21	C07K14	C07K14	A61K39	C07H21	G01N33	A61P35	C12N15	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
AVENTIS PHARMA SA
</APPLICANT-NAME>
<APPLICANT-NAME>
AVENTIS PHARMA S.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
SCHWEIGHOFFER FABIEN
</INVENTOR-NAME>
<INVENTOR-NAME>
TOCQUE BRUNO
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWEIGHOFFER, FABIEN
</INVENTOR-NAME>
<INVENTOR-NAME>
TOCQUE, BRUNO
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Peptide capable of modulating the levels of exchange of GDP with p21-GDP complexes, comprising the sequences SEQ ID No. 2, 3, 4, 6 or 8.
Peptide according to Claim 1, 
characterized in that
 it slows down or inhibits the exchange of GDP with the p21-GDP complex.
Peptide of sequence SEQ ID No. 2, 3, 4, 6 or 8.
Antibody or antibody fragment directed against a peptide according to any one of Claims 1 to 3.
Antibody or antibody fragment according to Claim 4, 
characterized in that
 it is directed against the peptide sequence SEQ ID No. 1.
Antibody or antibody fragment according to Claim 5, 
characterized in that
 it possesses the capacity to inhibit at least partially the exchange of GDP with the p21-GDP complex.
Nucleotide sequence coding for a peptide as is defined in any one of Claims 1 to 3.
Nucleotide sequence according to Claim 7, 
characterized in that
 it is chosen from:

(a) the sequences SEQ ID No. 1, 5 or 7 and that codes for a peptide capable of modulating the levels of exchange of GDP with p21-GDP complexes,
(b) the complementary strand of the sequences (a),
(c) the sequences derived from the sequences
 (a) and (b) as a result of the degeneracy of the genetic code.
Anti-sense sequence capable of inhibiting the production of peptides according to Claim 3 and derived from the sequences SEQ ID No. 1, SEQ ID No. 5 or SEQ ID No. 7 or from their complementary strand.
Use of a sequence according to Claim 8(b) for the 
in vitro
 detection of the expression of GDP exchange factor or for the demonstration of genetic abnormalities (incorrect splicing, polymorphism, point mutations).
Pharmaceutical composition comprising as active principle at least one peptide according to one of Claims 1 to 3 or an antibody or antibody fragment according to one of Claims 4 to 6 or a nucleotide sequence according to Claim 8.
Pharmaceutical composition according to Claim 11, intended for modulating the activation of p21 proteins.
Pharmaceutical composition according to Claim 12, intended for at least partially inhibiting the activation of p21 proteins.
Pharmaceutical composition according to Claim 11, intended for the treatment of cancers.
Use of an antibody or antibody fragment according to one of Claims 4 to 6 and/or of a nucleotide sequence according to Claim 8(b) for the detection of the expression and/or of an overexpression of an amplified, mutated or rearranged GDP exchange factor in a biological sample.
Use of an antibody or antibody fragment according to one of Claims 4 to 6 and/or of a nucleotide sequence according to Claim 8(b) for the 
in vitro
 typing of cancers.
Method for preparing a peptide according to any one of Claims 1 to 3, 
characterized in that
 a cell containing a nucleotide sequence according to Claim 7 is cultured under conditions for expression of
 the said sequence, and the peptide produced is recovered.
</CLAIMS>
</TEXT>
</DOC>
